Glenmark Pharmaceuticals Ltd has said that Glenmark Generics has been granted final approval for the Abbreviated New Drug Application (ANDA) by the US Food and Drug Administration (US FDA) for Nizatidine capsules and will start marketing immediately.
Nizatidine capsules are Glenmark's generic version of Axid by SmithKline Beecham Corporation and are indicated for up to 8 weeks for the treatment of active duodenal ulcer.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.